BBlogFlow

Women see multiple doctors to figure out menopause symptoms—exec says AI could connect the dots - Fortune

·1d ago

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email
Photo credit : From left: Ellie Austin, host, Fortune Daily; Reshema Kemps-Polanco, chief commercial officer, US, Novartis; Paula Schneider, CEO, Institute Advancing Women’s Health; Wendy Barnes, president and CEO GoodRX

For many women, menopause symptoms like sleep problems, joint stiffness, hot flashes, and more don’t bring just one doctor’s appointment—they bring multiple.

On average, women see “five or six doctors to try and figure out all the little parts and pieces of what’s going on with your body” once they hit perimenopause and menopause, Paula Schneider, CEO of the Institute Advancing Women’s Health, said Tuesday at the Fortune Most Powerful Women Summit in Santa Barbara, Calif. “And there’s no holistic health,” she said.

This article is an excerpt. To read the full content, visit the original source. Fortune

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·